Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87914
Title:
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
Authors:
Thatcher, Nick; De Campos, E S; Bell, D R; Steward, William P; Varghese, G; Morant, R; Vansteenkiste, J F; Rosso, R; Ewers, S B; Sundal, E; Schatzmann, E; Stocker, H
Abstract:
Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin alpha in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4-6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin alpha 150 IU kg(-1) subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg(-1) s.c. three times a week (n = 44). Reductions in epoetin alpha dosage were made during the study if Hb level increased to >15 g dl(-1). The mean weekly dosage was 335 and 612 IU kg(-1), respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin alpha-treated patients experienced anaemia (Hb < 10 g dl(-1)) during the course of chemotherapy (300 IU kg(-1), 39%; 150 IU kg(-1), 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg(-1), 20% (P< 0.001); 150 IU kg(-1), 45% (P< 0.05); untreated, 59%]. Epoetin alpha was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin alpha is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.
Affiliation:
CRC Department of Oncology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. 1999, 80 (3-4):396-402 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
May-1999
URI:
http://hdl.handle.net/10541/87914
DOI:
10.1038/sj.bjc.6690369
PubMed ID:
10408844
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.contributor.authorDe Campos, E Sen
dc.contributor.authorBell, D Ren
dc.contributor.authorSteward, William Pen
dc.contributor.authorVarghese, Gen
dc.contributor.authorMorant, Ren
dc.contributor.authorVansteenkiste, J Fen
dc.contributor.authorRosso, Ren
dc.contributor.authorEwers, S Ben
dc.contributor.authorSundal, Een
dc.contributor.authorSchatzmann, Een
dc.contributor.authorStocker, Hen
dc.date.accessioned2009-12-14T16:07:11Z-
dc.date.available2009-12-14T16:07:11Z-
dc.date.issued1999-05-
dc.identifier.citationEpoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. 1999, 80 (3-4):396-402 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid10408844-
dc.identifier.doi10.1038/sj.bjc.6690369-
dc.identifier.urihttp://hdl.handle.net/10541/87914-
dc.description.abstractAnaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin alpha in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4-6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin alpha 150 IU kg(-1) subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg(-1) s.c. three times a week (n = 44). Reductions in epoetin alpha dosage were made during the study if Hb level increased to >15 g dl(-1). The mean weekly dosage was 335 and 612 IU kg(-1), respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin alpha-treated patients experienced anaemia (Hb < 10 g dl(-1)) during the course of chemotherapy (300 IU kg(-1), 39%; 150 IU kg(-1), 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg(-1), 20% (P< 0.001); 150 IU kg(-1), 45% (P< 0.05); untreated, 59%]. Epoetin alpha was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin alpha is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.en
dc.language.isoenen
dc.subjectHaemoglobinsen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAnemia-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshCisplatin-
dc.subject.meshEpoetin Alfa-
dc.subject.meshErythrocyte Transfusion-
dc.subject.meshFemale-
dc.subject.meshHematinics-
dc.subject.meshHemoglobins-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshQuality of Life-
dc.titleEpoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.